Results 71 to 80 of about 2,022,996 (246)

AI‐Driven Cancer Multi‐Omics: A Review From the Data Pipeline Perspective

Advanced Intelligent Discovery, EarlyView.
The exponential growth of cancer multi‐omics data brings opportunities and challenges for precision oncology. This review systematically examines AI's role in addressing these challenges, covering generative models, integration architectures, Explainable AI for clinical trust, clinical applications, and key directions for clinical translation.
Shilong Liu, Shunxiang Li, Kun Qian
wiley   +1 more source

Genomic and transcriptomic profiling of combined small-cell lung cancer through microdissection: unveiling the transformational pathway of mixed subtype

Journal of Translational Medicine
Background Combined small-cell lung carcinoma (cSCLC) represents a rare subtype of SCLC, the mechanisms governing the evolution of cancer genomes and their impact on the tumor immune microenvironment (TIME) within distinct components of cSCLC remain ...
Wenjuan Ma, Ting Zhou, Mengmeng Song, Jiaqing Liu, Gang Chen, Jianhua Zhan, Liyan Ji, Fan Luo, Xuan Gao, Pansong Li, Xuefeng Xia, Yan Huang, Li Zhang   +12 more
doaj   +1 more source

Pan-cancer analysis of genomic properties and clinical outcome associated with tumor tertiary lymphoid structure

Scientific Reports, 2020
How the genomic landscape of a tumor shapes the formation of tertiary lymphoid structure (TLS) and how might TLS alter the clinical outcome or response to immunotherapy had not been systematically explored. Utilizing the genomic and transcriptome data of
Ziying Lin, Lixia Huang, ShaoLi Li, Jincui Gu, Xiaoxian Cui, Yanbin Zhou   +5 more
doaj   +1 more source

Neoantigen-specific CD4+ T cells sustain endogenous intratumoral B cell responses to enhance anti-tumor immunity 2258511

Introduction Cancer mutations can give rise to novel tumor-specific peptides (“neoantigens”) that are recognized by T cells to attack tumors.
Sean-Luc Shanahan, Tyler Jacks, David Klawon, Shalom Beyene   +3 more
core   +1 more source

Nanomedicine‐driven innovations in postoperative cancer immunotherapy: Remodeling tumor microenvironment and precision delivery strategies

BMEMat, EarlyView.
Nanomedicine‐Driven Strategies for Suppressing Postoperative Tumor Recurrence. This schematic illustrates three pivotal nanomedical strategies that synergistically counteract recurrence by targeting residual disease and the immunosuppressive tumor microenvironment within the surgical cavity.
Lisong Pang, Zhuomin Wang, Zhenhua Jin, Ahmed H. Ghonaim, Hengcheng Zhang, Xinyu You, Jinzhuo Ning, Jiaqing Cao, Yang Liu   +8 more
wiley   +1 more source

Treatment of patients with pMMR GI cancers with tumor-infiltrating lymphocytes (TIL): a reality?

A recent study published in Nature Medicine shows that adoptive cell therapy using neoantigen-selected tumor-infiltrating lymphocytes (TIL) is feasible in refractory metastatic gastrointestinal (GI) cancers, showing durable responses, especially when ...
Haanen, J.B.
core   +1 more source

Bridging the translational gap in clinical nanomedicine: From rational design to clinical reality

BMEMat, EarlyView.
Nanotechnology offers a multi‐faceted approach to modern healthcare, encompassing high‐sensitivity diagnostic imaging, innovative vaccine delivery, and targeted therapeutics. This review explores how these nanomedicine applications address critical challenges in cancer recurrence and the treatment of neurologic and respiratory diseases to combat rising
Ahmed H. Ghonaim, Marwa Ahmed El‐Naka, Wedad M. Nageeb, Atta Ullah Khan, Noura M. Seleem, Aliaa Abdelghafar, Doaa Zamel, Yang Liu, Qigai He, Wentao Li   +9 more
wiley   +1 more source

Tumor genomic alterations in severe-combined immunodeficiency bare-lymphocyte syndrome genes are associated with high mutational burden and disproportional neo-antigen rates

Journal for ImmunoTherapy of Cancer, 2019
The progression of cancer requires mutational adaptation to permit unrestrained proliferation. A fraction of cancer mutations are oncogenic drivers, while others are putative ‘passengers’ that do not contribute to oncogenesis.
Steve Lu, Yaomin Xu, Justin M. Balko
doaj   +1 more source

Cell surface marker-based capture of neoantigen-reactive CD8+ T-cell receptors from metastatic tumor digests

, 2023
Background Cellular immunotherapies using autologous tumor-infiltrating lymphocytes (TIL) can induce durable regression of epithelial cancers in selected patients with treatment-refractory metastatic disease.
Rami Yossef, Praveen D Chatani, Biman Paria, Paul Robbins, Victoria Hill, Frank J Lowery, Alakesh Bera, Satyajit Ray, Steven A Rosenberg, Maria Florentin, Jared J Gartner, Kyle J Hitscherich, Sri Krishna, Neilesh B Parikh, Maria Parkhust   +14 more
core   +1 more source

Obesity and Pathologic Response to Neoadjuvant Immunotherapy in Head and Neck Cancer: Preliminary Results From a Pilot Study

Head &Neck, EarlyView.
ABSTRACT Objective To evaluate associations between obesity and pathologic response to neoadjuvant immune checkpoint inhibitors (ICI) in patients with head and neck squamous cell carcinoma (HNSCC). Methods This was a retrospective cohort study conducted at a single tertiary academic center.
Angeline A. Truong, Laura Chen, Rex H. Lee, Xin Wu, Hyunseok Kang, Ivan H. El‐Sayed, Jonathan R. George, Chase M. Heaton, Ilya Likhterov, Michael Chow, Mary Jue Xu, Patrick K. Ha, Alain P. Algazi, Katherine C. Wai   +13 more
wiley   +1 more source